 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || IDE161 / Ideaya Biosci
Trial completion date, Trial primary completion date, Metastases: A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Dec 15, 2023
P1, N=68, Recruiting, Sponsor: IDEAYA Biosciences
- ||| IDE161 / Ideaya Biosci
Enrollment open, Metastases: A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - May 6, 2023
P1, N=68, Recruiting, Sponsor: IDEAYA Biosciences
Not yet recruiting --> Recruiting
- ||| IDE161 / Ideaya Biosci
New P1 trial, Metastases: A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Mar 28, 2023
P1, N=68, Not yet recruiting, Sponsor: IDEAYA Biosciences
- IDE161 / Ideaya Biosci
IDE161, a potential first-in-class clinical candidate PARG inhibitor, selectively targets homologous-recombination-deficient and PARP inhibitor resistant breast and ovarian tumors (Section 13; Poster Board #1) - Mar 14, 2023 - Abstract #AACR2023AACR_8590;
Moreover, studies in cell lines, tumors and tissues revealed that dose and time-dependent accumulation of PAR chains serves as a robust proximal pharmacodynamic biomarker indicative of PARG target engagement. IDE161 is a novel targeted therapy that exploits the synthetic lethal relationship between PARG and genomic instability, thus leading to selective anti-proliferative effects in tumors harboring defects in the HR pathway.
- || IDE161 / Ideaya Biosci
$IDYA IDEAYA Biosciences Announces Submission of IND Application to the U.S. FDA for PARG Development Candidate IDE161 https://t.co/Yw38s5IB82 (Twitter) - Dec 12, 2022
- Undisclosed PARG inhibitor / Ideaya Biosci
[VIRTUAL] Synthetic lethality of PARG inhibition in tumors with homologous recombination deficiencies () - Mar 13, 2021 - Abstract #AACR2021AACR_4463;
Furthermore, inhibition of cell proliferation by PARGi is antagonized by PARPi, which is consistent with an on-target cellular mechanism of action (MOA). In conclusion, PARGi induces significant accumulation of PAR chains and decreases cell proliferation both in vitro and in vivo in HR-deficient tumor cells.